JYSS BIO, a leading bioprocessing system provider, completed hundreds of millions of series B+ funding

Zhejiang Jinyi Shengshi Bioengineering Co., Ltd. (hereinafter referred to as "the company" or " JYSS BIO"), a single-use system provider for biopharmaceuticals, recently completed a B+ round of financing of several hundred million Renminbi, which was jointly led by Huatai International and Zhongjin Qiyuan. CICC Chuanyu and Kexing Holdings joined the investment, and the current shareholders Matrix Partners, Huarui Investment, Sherpa Investment, CITIC Medical Fund, Xiamen C &D continued to invest, and Gelu Capital continued to serve as the exclusive financial advisor. This round of financing will be mainly used to expand the production capacity of single-use bioreactors and bags, accelerate the research and development of new type of single-use bioreactors and related products, downstream systems and consumables, and be used for the construction of R&D center oversea and the expansion of oversea sales teams.

JYSS BIO is the first high-tech enterprise in China to realize the localization of the single-use bioreactors and disposable consumables. The company currently has 3,200 m² of B+A grade plant for consumables production complying to GMP, and has built a digital and automated production line for disposable consumables. The production performance and accuracy are customized complying to the latest European standards, with an annual production capacity of 800,000 sets. The company is expanding the 4,500m² B+A grade plant for general consumables production, which is expected to produce 1.8 million sets per year after it is put into operation. Meanwhile ,   workshop of 6,500 m² for bioreactor production, and a production base of about 27,000 m² for raw materials and accessories are under construction .

After years of continuous research and development, the company has launched the core product of single-use bioreactor, and its oxygen transfer mechanism obtained worldwide invention patent. The oxygen transfer mechanism has the advantages of high oxygen transfer efficiency and low shearing force, which can realize high-density cell cultivation and high cell viability, which lead to fast plant construction with low capital cost. In meanwhile, we can design and customize disposable cell culture bags, liquid storage and mixing equipment and consumables to meet the needs of biopharmaceutical customers.

The company has developed a number of innovative bioprocessing films independently with  patents for invention, which fully meet the requirements of domestic and worldwide regulations. The films with reliable biosafety and production applicability, can provide downstream manufacturers and with the same high quality as other imported brands. At present, the films have been applied in commercial production by many biopharmaceutical enterprises.

Single-Use bioreactor is the core facility for biopharmaceutical companies. With the rapid growth of global biopharmaceuticals and the rapid development of therapeutic technologies such as antibody drugs, vaccines, recombinant proteins, cell therapy, and gene therapy, biopharmaceutical companies have increasingly produced high-quality, low-cost, highly customized equipment and consumables. With increasing demands, the market size of single-use bioprocessing systems is greatly expanding. JYSS BIO firmly grasps the opportunities with the core technologies accumulated over the years, rapidly develops new application fields of products, continuously improves product quality, and achieves leap-forward development.

Focusing on the core goal of providing customers with high quality products, the company continues to strengthen its own strength to meet the needs of the rapid industry development . Based on broad development prospects, advanced talent concept and incentive mechanism, the company has won the recognition of outstanding talents from many multinational companies, and has continuously absorbed the core talents in the industry. Those talents have made great contributions to promote the company's technology upgrading and industrial chain expansion, providing a lasting impetus for the company's future development, and fully demonstrating that the company's position in the industry is becoming more and more solid.

In terms of research and development, the company has built a comprehensive R&D platform with the core technology of single-use bioreactors as a fulcrum, carried out iterative upgrade of existing products and development of new products, and established a dedicated team to develop downstream process solutions. We aim to provide our customers with more integrated solutions.

In terms of manufacturing capacity, the company has built new production workshops in Huzhou and Hangzhou respectively for consumables and bioreactor assembly, and entered Blue Bay in Lingang New Area of Shanghai Free Trade Zone in September 2021, where a new workshop for downstream bioprocessing products will be built. The manufacturing base has laid a solid foundation for the long-term development of the enterprise in terms of hardware and infrastructure. In December 2021, the company officially launched the base construction project in Huzhou for consumables production covering an area of 21.72 acres and a construction area of around 27,000m². The production of raw materials and accessories for single-use assemblies such as silicon tubes, connectors, filters and outer packaging helps the company to fully deploy the industrial chain layout on localization of   disposable consumables, raw materials and accessories.

In the vaccines, gene therapy, cell therapy, antibody drugs etc. area, the company's products have been recognized by more and more customers. Facing the huge market, the company's management team fully realizes that the competition among upstream biopharmaceutical companies is not for individual products, but for overall process solutions. By synergy the overall industry chain advantages, we can meet the biopharmaceutical customer demand on upstream products to the greatest extent.

JYSS BIO takes the single-use bioreactor as a fulcrum and continuously expands its product portfolio throughout the overall process for biopharmaceuticals. The disposable consumables such as liquid mixing bags and storage bags have been used in well-known domestic manufacturers of vaccines, antibodies, gene therapy, etc. After years of research and application exploration, the special bioprocess film for biopharmaceuticals have been commercialized. , more types of films will be launched in future. Since currently single-use assemblies (aseptic connection/disconnection, , filters, connectors, etc.) mainly rely on importing, JYSS BIO has mastered the processing and manufacturing technology based on years of research for common used accessories to achieve substitution. In the upstream and downstream process of cell culture, the company is also actively expand the product lines and industrial layout.

Under the rapid expansion of the single-use market and the continuous accelerated pace on substitution of imports, JYSS BIO always has clear understanding of the company's current situation, development strategy and external environment, and will firmly grasp of the opportunity, and keep the pace with development. Through multiple rounds of financings, the company not only obtained sufficient funds, but also obtained abundant industrial resources. With its own strong base and the help of external partners, it is believed that JYSS BIO will surely advance into a leading bioprocess enterprise!